Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecamylamine for Autonomic Dysreflexia Prophylaxis
NCT03914677Phase 4Unknown
- Sponsor
- Wayne State University
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecamylamine in autonomic dysreflexia (AD), sponsored by Wayne State University. Primary endpoints: Change in Systolic Blood Pressure at 10 minutes and Change in Heart Rate at 10 minutes. Status: unknown.
02
Drugs
mecamylamine
03
Conditions
autonomic dysreflexia (AD)
Beyond the preview
Go deeper on NCT03914677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914677.